• Home
  • KU Leuven
  • Department of Mechanical Engineering
  • Alexandros Leonidakis
Alexandros Leonidakis

Alexandros Leonidakis
KU Leuven | ku leuven · Department of Mechanical Engineering

PhD

About

12
Publications
419
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
23
Citations

Publications

Publications (12)
Article
Full-text available
Biomarkers of bone turnover in serum are suggestive of bone dynamics during treatment in multiple myeloma (MM). We evaluated the role of daratumumab on bone remodeling among patients with relapsed/refractory MM in the prospective, open-label, phase 2 study REBUILD. Daratumumab was administered according to the approved indication. A total of 33 out...
Article
Introduction Despite the availability of novel agents in treating multiple myeloma (MM), renal impairment (RI) remains a poor prognostic factor, and the median survival of patients (pts) with MM and RI is approximately half of that for MM pts with normal renal function. RI can affect up to 50% of pts with MM at presentation, highlighting the need f...
Article
Introduction The use of lenalidomide in frontline therapy for patients (pts) with newly diagnosed multiple myeloma (NDMM) has increased the number of pts who become refractory to lenalidomide at second line. Thus, there is an ongoing need for new treatment options for lenalidomide refractory patients at first relapse. Daratumumab, an anti-CD38 mono...
Article
Introduction: In systemic light chain (AL) amyloidosis free light chains produced by clonal plasma cells form amyloid fibrils that are deposited in tissues and organs resulting in organ dysfunction. Cardiac involvement by AL amyloidosis is frequent and the most critical prognostic factor. Prognostic evaluation in AL is based on cardiac biomarkers a...
Article
Introduction: Systemic light chain (AL) amyloidosis is a rare progressive and debilitating disease which is caused by the abnormal production of amyloidogenic free light chains by a plasma cell clone. Substantial heterogeneity in clinical presentation of AL leads to difficulties in the early and correct diagnosis, as well as special challenges in m...
Article
Full-text available
Introduction: Lenalidomide-based regimens are currently among the standard-of-care treatment options for newly diagnosed patients with multiple myeloma NDMM). Second-line treatment of patients who are refractory to lenalidomide or have relapsed after prior use of lenalidomide is challenging. Daratumumab, an IgG1κ human monoclonal antibody that targ...
Article
Full-text available
Introduction: Osteolytic lesions (OL) is a devastating characteristic of multiple myeloma (MM) that decreases patients (pts) quality of life. The interaction between MM plasma cells and the bone microenvironment leads to intracellular and intercellular pathways that adversely alter the delicate balance between bone formation and bone resorption. Pr...
Article
Full-text available
Introduction: A major clinical feature of multiple myeloma (MM) is osteolytic bone disease, with bone resorption prevailing bone formation. Daratumumab, an IgG1κ human monoclonal antibody that targets CD38, has been licensed for use in patients (pts) with relapsed or refractory MM (RRMM); however, its effect on bone disease has not yet been determi...
Article
Statement of significance: Fibrin is a natural biopolymer that has drawn much interest as a biomimetic carrier in tissue engineering applications. We hereby use a novel combined approach for the structural characterization of fibrin networks based on optical microscopy and light scattering methods that can also be applied to other fibrillar hydrog...

Network

Cited By